Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Journal of Clinical Oncology · 01.07.2023 · 41 (19) · 3534-3544
DOI: 10.1200/jco.22.01935 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2023. Verfasst von Claire N Harrison und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Polycythemia Vera. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Cancer Research UK.
Abstract (Originalsprache)
PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC-PV is a randomized phase II trial of ruxolitinib versus best available therapy (BAT) in patients resistant/intolerant to hydroxycarbamide (HC-INT/RES). Primary outcome was complete response (CR) within 1 year. Secondary outcomes included duration of response, event-free survival (EFS), symptom, and molecular response. RESULTS One hundred eighty patients were randomly assigned. CR was achieved in 40 (43%) patients on ruxolitinib versus 23 (26%) on BAT (odds ratio, 2.12; 90% CI, 1.25 to 3.60; P = .02). Duration of CR was superior for ruxolitinib (hazard ratio [HR], 0.38; 95% CI, 0.24 to 0.61; P < .001). Symptom responses were better with ruxolitinib and durable. EFS (major thrombosis, hemorrhage, transformation, and death) was superior for patients attaining CR within 1 year (HR, 0.41; 95% CI, 0.21 to 0.78; P = .01); and those on ruxolitinib (HR, 0.58; 95% CI, 0.35 to 0.94; P = .03). Serial analysis of JAK2V617F variant allele fraction revealed molecular response was more frequent with ruxolitinib and was associated with improved outcomes (progression-free survival [PFS] P = .001, EFS P = .001, overall survival P = .01) and clearance of JAK2V617F stem/progenitor cells. ASXL1 mutations predicted for adverse EFS (HR, 3.02; 95% CI, 1.47 to 6.17; P = .003). The safety profile of ruxolitinib was as previously reported. CONCLUSION The MAJIC-PV study demonstrates ruxolitinib treatment benefits HC-INT/RES PV patients with superior CR, and EFS as well as molecular response; importantly also demonstrating for the first time, to our knowledge, that molecular response is linked to EFS, PFS, and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
- Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.
- Wellcome Sanger Institute Hinxton, Cambridgeshire, United Kingdom.
- Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, United Kingdom.
ORCID-Profile: Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, Christina Yap, Isaak Ailts, Amylou C Dueck, Ruben A Mesa, William G Dunn, Mamta Garg, Steven Knapper, Josephine Crowe, Ioannis Koutsavlis, Siamak Arami, Jennifer Byrne, Elizabeth Joanna Baxter, Mary Frances McMullin, Adam J Mead
Förderung
- Medical Research Council
- Cancer Research UK
Zitieren
APA
Harrison, C. N., Nangalia, J., Boucher, R., Jackson, A., Yap, C., O'Sullivan, J., Fox, S., Ailts, I., Dueck, A. C., Geyer, H. L., Mesa, R. A., Dunn, W. G., Nadezhdin, E., Curto-Garcia, N., Green, A., Wilkins, B., Coppell, J., Laurie, J., Garg, M., …, & Mead, A. J. (2023). Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. Journal of Clinical Oncology, 41(19), 3534-3544. https://doi.org/10.1200/jco.22.01935
Vancouver
Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O'Sullivan J, et al. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial. Journal of Clinical Oncology. 2023;41(19):3534-3544. doi:10.1200/jco.22.01935
BibTeX
@article{Harrison2023,
author = {Harrison, Claire N and Nangalia, Jyoti and Boucher, Rebecca and Jackson, Aimee and Yap, Christina and O'Sullivan, Jennifer and Fox, Sonia and Ailts, Isaak and Dueck, Amylou C and Geyer, Holly L and Mesa, Ruben A and Dunn, William G and Nadezhdin, Eugene and Curto-Garcia, Natalia and Green, Anna and Wilkins, Bridget and Coppell, Jason and Laurie, John and Garg, Mamta and Ewing, Joanne and Knapper, Steven and Crowe, Josephine and Chen, Frederick and Koutsavlis, Ioannis and Godfrey, Anna and Arami, Siamak and Drummond, Mark and Byrne, Jennifer and Clark, Fiona and Mead-Harvey, Carolyn and Baxter, Elizabeth Joanna and McMullin, Mary Frances and Mead, Adam J},
title = {Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {19},
pages = {3534--3544},
doi = {10.1200/jco.22.01935}
}
EUVIMED